Brief Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 14, 2010; 16(42): 5347-5352
Published online Nov 14, 2010. doi: 10.3748/wjg.v16.i42.5347
Table 1 Costs of procedures and stents in US dollars1
Year
2000200120022003200420052006200720082009
ERCP56.4553.6953.6258.1462.1871.5779.4883.6176.8971.45
ERBD175.48153.70153.50166.46178.02204.88227.50239.33204.24178.73
PTBD91.6681.6081.4888.3794.51108.77120.77127.06150.52168.09
PTBD tube change26.6534.6134.5737.4940.0946.1451.2353.9067.7177.82
SEMS697.80611.19628.53661.92689.23770.21825.67810.86688.32641.93
PS60.4752.9654.4657.3659.7266.7471.5574.0259.5555.54
Table 2 Patient characteristics
SEMS groupPS groupP value
No. of patients2927
Gender (M:F)18:1119:80.512
Age at initial SEMS insertion, median (yr)66660.352
Diagnoses0.277
Pancreatic cancer156
Common bile duct cancer35
Hilar cholangiocarcinoma44
Gallbladder cancer36
Metastatic lymph nodes32
Ampulla of Vater cancer13
Hepatocellular carcinoma01
Anti-cancer therapy21150.188
Table 3 Comparison of self-expandable metal stent and plastic stent in subsequent endoscopic retrograde biliary drainage (mean ± SD) n (%)
SEMS group (n = 29)PS group (n = 27)P value
Follow-up period, median (d)2001330.993
Stent occlusion16 (55.2)18 (66.7)0.379
Time to stent occlusion, median (d)11861010.118
Overall stent patency, median (d)1,279660.379
No. of additional biliary drainage procedures2.54 ± 4.121.85 ± 1.950.457
Total cost of subsequent biliary drainage procedures ($)410.04 ± 692.60630.16 ± 671.630.260
Survival after subsequent ERBD, median (d)12001330.225
Table 4 Univariate analysis of factors associated with time to second stent occlusion
FactorTime to second stent occlusion, median (d)P value
Sex0.273
Male (n = 37)103
Female (n = 19)137
Age at initial SEMS insertion (yr)0.697
≥ 65 (n = 31)137
< 65 (n = 25)104
Diagnosis0.363
Pancreatic cancer (n = 21)137
Others (n = 35)103
Biliary drainage prior to initial SEMS insertion0.924
Yes (n = 24)137
No (n = 32)104
Cause of initial SEMS occlusion0.008
Ingrowth (n = 44)101
Not ingrowth (n = 12)268
Anti-cancer therapy0.444
Yes (n = 36)137
No (n = 20)103
Cholangitis on initial SEMS occlusion0.244
Yes (n = 33)103
No (n = 23)186
Covered initial SEMS0.918
Yes (n = 4)186
No (n = 52)104